Company Profile
Amarin Corporation Stock Price, News & Analysis
- Ticker:
- AMRN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland and listed in the U
Stock performance
14.26 USD (-1.04%)
Close
Last updated: August 6, 2026
303M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AMRN closed down 1.04% at $14.26. No new same-company headline was identified in the current news window.
Company overview
Cardiovascular Pharmaceutical Company
Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities.
Partnered International Model
Amarin shifted to a fully partnered international commercial strategy, including a long-term license and supply agreement with Recordati for Europe-focused commercialization across 59 countries. This model reduced operating expenses while allowing partners with local expertise to drive pricing, reimbursement, market access, and adoption.
U.S. Branded IPE Presence
In the United States, Amarin continues to maintain a leading branded IPE position despite generic competition. The company's U.S. IPE market share increased to 48% in the second quarter of 2026, while branded VASCEPA prescriptions rose year over year.
Strategic Position
Amarin is best understood as a focused cardiovascular company transitioning from direct global commercialization to a leaner partner-led international model. Its near-term performance depends on international volume growth, stable U.S. branded share, disciplined operating expenses, and positive cash flow generation.
Future catalysts
Near-term commercialization progress in Singapore and South Korea.
Recent news
- 01
- 02
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Source: Amarin Corporation
- 03
- 04
- 05
Amarin Reports 2026 First Quarter Financial Results
Source: Amarin Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amarin Corporation (AMRN)?
Amarin Corporation (AMRN) most recently closed at 14.26 USD, a -1.04% move versus the previous session.
What is the market cap of Amarin Corporation (AMRN)?
Amarin Corporation currently has a market capitalization of 303M USD on BioPharmSignal.
What does Amarin Corporation do?
Cardiovascular Pharmaceutical Company Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities. Partnered International Model Amarin shifted to a fully partnered...
On which exchange is AMRN stock listed?
Amarin Corporation (AMRN) is associated with NASDAQ, Ireland and listed in the U, Biopharma.
What is Cardiovascular?
Cardiovascular Pharmaceutical Company Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden.
Which conditions is Amarin Corporation targeting with Cardiovascular?
Amarin Corporation is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Amarin Corporation describe recent progress with Cardiovascular?
Near-term commercialization progress in Singapore and South Korea.
What is Pharmaceutical?
Cardiovascular Pharmaceutical Company Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden.